A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal ...

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...